著者

Zhao-qiang Zhang Xiao Sun Bing-xiang Wang Yan-ling Zhang

出版者

Japan Brain Science society

雑誌

脳科学誌 (ISSN:13415301)

巻号頁・発行日

vol.36, pp.50-60, 2011-03-30 (Released:2017-06-01)

参考文献数

10

---

Objective Modeling a surgery hypertensive rat model, observe the changes of the expression of ACE and ACE2 in various groups, thus for further research of the pathogenesis of hypertension. Methods Twenty-eight Sprague- Dawley rats were used, which were divided randomly into four groups. One group served as control (n=7), others as hypertensive group (n=7), enalapril group [n=7,15mg/(kg・d)] and losartan group [n=7,15mg/(kg・d)]. All rats were operated as surgery hypertension except rats of control group. Renal artery was ligated. Enalapril and losartan were used as treatments of rats of enalapril group and losartan group after surgery. Blood pressure of rats was measured by arteria caudilis uninjured. The expression of renal ACE and ACE2 mRNA were measured by RT-PCR. The expression of renal ACE and ACE2 protein were measured by immunohistochemistry. Results Blood pressure of rats was increased after operation. The expression of ACE and ACE2 mRNA and protein in various groups were different. The expression of ACE mRNA and protein of Hypertensive group were higher than others. The expression of ACE2 mRNA and protein of losartan group were higher than others. Conclusion Model of surgery hypertensive rats were success by the ligation of renal artery. It's a Simple, reliable and cheap method of hypertensive rat model. The imbalance between the expression of ACE and ACE2 is one of the important roles of pathogenesis of hypertension.

著者

Xin LU Xiang WANG Lin PANG Jiayi LIU Qinghai YANG Xingchen SONG

出版者

The Institute of Electronics, Information and Communication Engineers

雑誌

IEICE Transactions on Fundamentals of Electronics, Communications and Computer Sciences (ISSN:09168508)

巻号頁・発行日

vol.E104.A, no.11, pp.1629-1643, 2021-11-01 (Released:2021-11-01)

参考文献数

38

被引用文献数

2

---

Network Slicing (NS) is recognized as a key technology for the 5G network in providing tailored network services towards various types of verticals over a shared physical infrastructure. It offers the flexibility of on-demand provisioning of diverse services based on tenants' requirements in a dynamic environment. In this work, we focus on two important issues related to 5G Core slices: the deployment and the reconfiguration of 5G Core NSs. Firstly, for slice deployment, balancing the workloads of the underlying network is beneficial in mitigating resource fragmentation for accommodating the future unknown network slice requests. In this vein, we formulate a load-balancing oriented 5G Core NS deployment problem through an Integer Linear Program (ILP) formulation. Further, for slice reconfiguration, we propose a reactive strategy to accommodate a rejected NS request by reorganizing the already-deployed NSs. Typically, the NS deployment algorithm is reutilized with slacked physical resources to find out the congested part of the network, due to which the NS is rejected. Then, these congested physical nodes and links are reconfigured by migrating virtual network functions and virtual links, to re-balance the utilization of the whole physical network. To evaluate the performance of deployment and reconfiguration algorithms we proposed, extensive simulations have been conducted. The results show that our deployment algorithm performs better in resource balancing, hence achieves higher acceptance ratio by comparing to existing works. Moreover, our reconfiguration algorithm improves resource utilization by accommodating more NSs in a dynamic environment.

著者

Yong-Qiang Shan Yan-Ping Zhu Jing Pang Yan-Xiang Wang Dan-Qing Song Wei-Jia Kong Jian-Dong Jiang

出版者

公益社団法人日本薬学会

雑誌

Biological and Pharmaceutical Bulletin (ISSN:09186158)

巻号頁・発行日

vol.36, no.10, pp.1562-1569, 2013-10-01 (Released:2013-10-01)

参考文献数

41

被引用文献数

11 40

---

This study was designed to improve the absorption and hypoglycemic efficacy of berberine (BBR), which is a substrate of P-glycoprotein (P-gp), by combination with a P-gp inhibitor tetrandrine (Tet). Flow cytometry and LC-MS/MS were used to determine the cellular efflux or retention of chemicals. Pharmacokinetic study was performed in ICR mice following oral administration of the study compounds. The hypoglycemic efficacies of the compounds were evaluated in diabetic KK-Ay mice. In the in vitro experiments, Tet significantly inhibited the efflux and increased the uptake of P-gp substrates rhodamine-123 as well as BBR in MCF7/DOX cells and Caco-2 intestinal cells. Meanwhile, Tet greatly reduced the expression of P-gp in Caco-2 cells. The inhibition of BBR efflux by Tet was translated into improved pharmacokinetics in vivo. When co-administered, Tet dose-dependently increased the average maximum concentration (Cmax) and area under concentration–time curve (AUC0–24) of BBR in mice. Tet itself had no impact on glucose metabolism. However, it greatly potentiated the hypoglycemic efficacy of BBR in diabetic KK-Ay mice. In addition, we found that Tet had moderate inhibitory effect on the catalytic activity of CYP3A4, which played a role in the bio-transformation of BBR, and this may also take part in the improvement of the pharmacokinetics of BBR. In summary, combination with P-gp inhibitors such as Tet can improve the pharmacokinetics and hypoglycemic efficacy of BBR greatly; this implicates a feasible strategy for exploring the therapeutic effects of BBR and other pharmaceuticals which are substrates of P-gp.